Lewisville Medical Pharmacy
Outcome
DEA issued Order to Show Cause and Immediate Suspension June 9, 2021; ALJ recommended revocation April 2022; DEA revoked Certificate of Registration No. FL2190332 effective October 31, 2022, for failure to resolve red flags related to controlled substance prescriptions.
Details
Lewisville Medical Pharmacy — DEA Immediate Suspension and Revocation (2021–2022)
Outcome: DEA issued an Order to Show Cause and Immediate Suspension of Registration on June 9, 2021; after a four-day administrative hearing, the ALJ recommended revocation on April 1, 2022; DEA Administrator Anne Milgram signed the final Decision and Order on September 26, 2022, revoking DEA Certificate of Registration No. FL2190332, effective October 31, 2022.
On June 9, 2021, the Drug Enforcement Administration issued an Order to Show Cause and Immediate Suspension of Registration to Lewisville Medical Pharmacy of Lewisville, Texas. The agency alleged that the pharmacy's continued registration was inconsistent with the public interest based on the pharmacy's failure to properly resolve red flags related to controlled substance prescriptions.
DEA Administrative Law Judge Paul E. Soeffing conducted a four-day video teleconference hearing from November 15 through 18, 2021. On April 1, 2022, the ALJ issued his Recommended Decision recommending revocation of the pharmacy's DEA registration. Among the issues identified during the proceedings were problems with customer address information in patient profiles — a category of red flags that pharmacists are required to investigate and resolve before dispensing controlled substances.
DEA Administrator Anne Milgram signed the final Decision and Order on September 26, 2022. The order revoked the pharmacy's DEA Certificate of Registration No. FL2190332, denied any pending renewal or modification applications, and denied any pending applications for additional DEA registration in Texas. The order became effective October 31, 2022. The Decision and Order was published in the Federal Register on September 30, 2022.
Primary Source: Lewisville Medical Pharmacy; Decision and Order (Fed. Reg. Sep. 30, 2022)
How Crucible Prevents This
The DEA case against Lewisville Medical Pharmacy involved failures in red-flag resolution, including issues with customer address information in patient profiles. Crucible's structured patient profile verification controls — requiring current, documented address verification for controlled substance patients and flagging address anomalies before dispensing — would have caught these issues at the point of fill.
Don't let this happen to your organization. See how Crucible works.
See How Crucible Works